Disease

Medullary thyroid gland carcinoma

Also known as C cell carcinoma, MTC, carcinoma of parafollicular cell, carcinoma, C-cell, malignant+18 more

C cell carcinoma, MTC, carcinoma of parafollicular cell, carcinoma, C-cell, malignant, medullary carcinoma, medullary carcinoma of the thyroid, medullary carcinoma of the thyroid gland, medullary carcinoma of thyroid, medullary carcinoma of thyroid gland, medullary thyroid cancer, medullary thyroid carcinoma, parafollicular cell carcinoma, thyroid gland medullary cancer, thyroid gland medullary carcinoma, thyroid gland neuroendocrine carcinoma, thyroid medullary carcinoma, ultimobranchial thyroid tumor, ultimobranchial thyroid tumour, THME, medullary thyroid cancer (MTC), thyroid cancer, medullary, thyroid carcinoma, medullary.

Associated genes

Related proteins

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

No activity recorded in this window. Try a wider timeframe.

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies

Selpercatinibapproved

Approval — Retsevmo as monotherapy is indicated for the treatment of adults with: advanced RET fusi… (2021)

Cabozantinibapproved

Approval — Treatment of adult patients with progressive, unresectable locally advanced or metastatic… (2014)

Vandetanibapproved

Approval — Caprelsa is indicated for the treatment of aggressive and symptomatic medullary thyroid c… (2012)

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals

2021emaApproval — Selpercatinib· Retsevmo as monotherapy is indicated for the treatment of adults with: advanced RET fusion positive non small cell lung cancer (NSCLC) not previously treated with a RET inhibitor. For biomarker-based patient selection, see section 4.2.  Retsevmo as monotherapy is indicated for the treatment of adults and paediatric patients 2  years of age and older with: advanced RET fusion positive thyroid cancer who are radioactive iodine-refractory (if radioactive iodine is appropriate) . For biomarker-based patient selection, see section 4.2. advanced RET mutant medullary thyroid cancer (MTC) . For biomarker-based patient selection, see section 4.2. advanced RET fusion positive solid tumours, when treatment options not targeting RET provide limited clinical benefit, or have been exhausted (see sections  4.4 and 5.1). For biomarker-based patient selection, see section 4.2. source ↗

2014emaApproval — Cabozantinib· Treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma. source ↗

2012emaApproval — Vandetanib· Caprelsa is indicated for the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. Caprelsa is indicated in adults, children and adolescents aged 5 years and older. For patients in whom re-arranged-during-transfection(RET) mutation is not known or is negative, a possible lower benefit should be taken into account before individual treatment decision. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Associated genes

12 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

RET0.86 CCDC60.61 PTK60.59 MET0.59 EPHA30.57 FLT10.55 ERBB40.55 SRC0.55 TEK0.54 EPHB30.54 ERBB30.54 KIF5B0.54

Disease biology

9 matches

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Proto-oncogene tyrosine-protein kinase receptor Retvia RET0.86 Coiled-coil domain-containing protein 6via CCDC60.61 Hepatocyte growth factor receptorvia MET0.59 Vascular endothelial growth factor receptor 1via FLT10.55 Receptor tyrosine-protein kinase erbB-4via ERBB40.55 Proto-oncogene tyrosine-protein kinase Srcvia SRC0.55 Angiopoietin-1 receptorvia TEK0.54 Receptor tyrosine-protein kinase erbB-3via ERBB30.54 Kinesin-1 heavy chainvia KIF5B0.54

Reference

Authoritative identity, definition & identifiers.

Synonyms

References & data sources

Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
Related entities are derived from literature co-mention (studied together) — associative, not causal.